Moderna (MRNA)
(Delayed Data from NSDQ)
$107.97 USD
+1.79 (1.69%)
Updated Apr 26, 2024 03:59 PM ET
After-Market: $107.85 -0.12 (-0.11%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Company Summary
Cambridge, MA-based Moderna, Inc. is a commercial-stage pharmaceutical company primarily focused on discovering and developing messenger-RNA (mRNA) based therapies.
Currently, Moderna generates all its product revenues from the sale of its COVID-19 vaccines, which are approved/authorized for use in multiple countries in individuals as young as six months, either as primary two-dose regimens or as booster doses.
Moderna also has several promising pipeline candidates in different stages of development, targeting multiple indications including cancer and cardiovascular. It is also developing a few prophylactic vaccines and cancer vaccines.
<...
Company Summary
Cambridge, MA-based Moderna, Inc. is a commercial-stage pharmaceutical company primarily focused on discovering and developing messenger-RNA (mRNA) based therapies.
Currently, Moderna generates all its product revenues from the sale of its COVID-19 vaccines, which are approved/authorized for use in multiple countries in individuals as young as six months, either as primary two-dose regimens or as booster doses.
Moderna also has several promising pipeline candidates in different stages of development, targeting multiple indications including cancer and cardiovascular. It is also developing a few prophylactic vaccines and cancer vaccines.
The company has 45 mRNA-based investigational candidates with many candidates in the clinical development stage. Key candidates in the mRNA pipeline are mRNA-1647, mRNA-1010, mRNA-1345 and mRNA-4157, which are currently either in regulatory review or undergoing late-stage development. mRNA-1647 is being evaluated as a cytomegalovirus (CMV) vaccine, mRNA-1010 is a flu vaccine and mRNA-1345 is being developed as a respiratory syncytial virus (RSV) vaccine. mRNA-4157 is an individualized neoantigen therapy (INT) currently being tested across multiple cancer indications.
Apart from the above candidates, Moderna is also evaluating mRNA-based investigational candidates in multiple mid-stage and early-stage stages of clinical studies, targeting various indications, including Zika virus and propionic acidemia.
Moderna's mRNA technology has helped it to enter into several collaborations with large pharma/biotech companies, namely Merck and Vertex Pharmaceuticals. It also has strategic alliances with some government-sponsored organizations and private foundations.
Moderna recorded total revenues of $6.8 billion in 2023, down 64% year over year.
General Information
Moderna, Inc
200 TECHNOLOGY SQUARE
CAMBRIDGE, MA 02139
Phone: 617-714-6500
Fax: NA
Email: ir@modernatx.com
Industry | Medical - Biomedical and Genetics |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 3/31/2024 |
Earnings Date | 5/2/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | -3.59 |
Current Year EPS Consensus Estimate | -7.51 |
Estimated Long-Term EPS Growth Rate | 17.60 |
Earnings Date | 5/2/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 106.18 |
52 Week High | 142.79 |
52 Week Low | 62.55 |
Beta | 1.62 |
20 Day Moving Average | 2,940,287.00 |
Target Price Consensus | 131.75 |
4 Week | -0.36 |
12 Week | 7.23 |
YTD | 6.77 |
4 Week | 3.71 |
12 Week | 4.21 |
YTD | 0.88 |
Shares Outstanding (millions) | 382.88 |
Market Capitalization (millions) | 40,654.16 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | NA |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | NA |
Trailing 12 Months | NA |
PEG Ratio | NA |
vs. Previous Year | -84.76% |
vs. Previous Quarter | 139.57% |
vs. Previous Year | -44.71% |
vs. Previous Quarter | 53.52% |
Price/Book | 2.92 |
Price/Cash Flow | NA |
Price / Sales | 5.94 |
3/31/24 | NA |
12/31/23 | -10.23 |
9/30/23 | -2.14 |
3/31/24 | NA |
12/31/23 | -7.70 |
9/30/23 | -1.60 |
3/31/24 | NA |
12/31/23 | 3.42 |
9/30/23 | 2.46 |
3/31/24 | NA |
12/31/23 | 3.36 |
9/30/23 | 2.35 |
3/31/24 | NA |
12/31/23 | -23.57 |
9/30/23 | -4.01 |
3/31/24 | NA |
12/31/23 | -68.84 |
9/30/23 | -38.00 |
3/31/24 | NA |
12/31/23 | -57.56 |
9/30/23 | -25.84 |
3/31/24 | NA |
12/31/23 | 36.33 |
9/30/23 | 35.29 |
3/31/24 | NA |
12/31/23 | 8.79 |
9/30/23 | 7.88 |
3/31/24 | NA |
12/31/23 | 0.04 |
9/30/23 | 0.04 |
3/31/24 | NA |
12/31/23 | 3.98 |
9/30/23 | 4.10 |